Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
The purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD). In addition, the study will evaluate preliminary proof of concept endpoints in COPD subjects such as biomarkers in sputum and mucociliary clearance.
Detailed description
The proposed initial trial in healthy subjects and subjects with mild COPD will establish the tolerability of PUR118 in these subjects over single and short multi-day dosing periods. The study will also provide preliminary data regarding PUR118's potential impact on biomarkers in COPD. Finally, this trial will assess PUR118's effect on mucociliary clearance. This is a four part study enrolling healthy volunteers in a single ascending dose design (SAD; Part I), followed by multiple ascending dose design (MAD; Part II). Contingent on demonstration of safety in a healthy subject population, the study will enroll mild COPD subjects for a short multi-dose design (Part III) incorporating safety and pharmacodynamic endpoints. Lastly Part IV of the trial will assess the effect of PUR118 on mucociliary clearance in mild COPD subjects.
Interventions
DRUGPUR118
inhaled
Sponsors
Quotient Bioresearch
Pulmatrix Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Main Inclusion Criteria Parts I & II * Healthy males or non pregnant, non lactating healthy females; * Age 18-65 years of age; * Must be willing and able to communicate in English and participate in the whole study; * Must provide written informed consent. Main
Exclusion criteria
Parts I & II * Current smokers and those who have smoked within the last 12 months; * Females of child bearing age not willing to use an acceptable form of contraception; * Presence or history of allergy requiring treatment; * Serious adverse reaction or hypersensitivity to any drug; Main Inclusion Criteria: Parts III and IV * Males or non pregnant, non lactating females; * Age 45-70 years; * Current (Part III only) or ex-smokers who at least a 15 pack-year smoking history. For Part IV, subjects must be non-smokers for at least 3 months; * Medically stable, with no evidence of uncontrolled co-existing conditions at screening; * Must not be taking any inhaled or oral corticosteroids; * FEV1/FVC ratio \<70% and FEV1 60 - 80% (or \>/= 60% for Part IV only) of predicted following administration of a bronchodilator; * Patients must have a medical history of COPD confirmed by their General Practitioner (GP) or treating hospital physician or must have a chest x-ray (CXR) which is normal or consistent with mild COPD and excludes other clinically significant respiratory abnormalities; * Must be willing and able to communicate in English and participate in the whole study; * Must provide written informed consent. Main
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability assessed by changes in clinical signs and symptoms, clinical safety laboratory tests, vital signs, ECG, spirometry, oxygen saturation, telemetry and adverse events | 2 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of biomarkers of inflammation and COPD in induced sputum in mild COPD subjects after short multi-dosing with PUR118 compared to baseline | 2 days |
| Assessment of changes in mucociliary clearance after treatment with PUR118 in mild COPD subjects compared to baseline | single dose |
Countries
United Kingdom
Outcome results
None listed